We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Risk-Averse FDA Strangles 510(k) Process, New Citizen’s Petition Charges

Risk-Averse FDA Strangles 510(k) Process, New Citizen’s Petition Charges

January 18, 2013

A citizen’s petition filed by Minneapolis law firm DuVal & Associates challenges several aspects of the 510(k) process, charging that current practices effectively overstep CDRH’s statutory boundaries and insert the agency into the practice of medicine.

The petition asks the FDA to hold off on implementing the December 2011 draft guidance on determining substantial equivalence and instead abide by pre-2009 documents on the 510(k) process. It also requests an ongoing training program involving both FDA and industry and a review of 510(k) program staff that considers possibly contracting out review work.

Attorney Mark DuVal said his concerns are systemic, rather than being tied to any single device or therapeutic segment. While he’s seen improvements from upper-level FDA management since passage of reform legislation tied to MDUFA, he feels the message has yet to filter down to rank-and-file reviewers.

For more than 35 years, Devices & Diagnostics Letter has been a must-read for leaders in the device and diagnostics industries who need to stay in compliance and avoid costly design and production mistakes. Each weekly issue provides the latest regulatory news, and tells you how to slash research time, speed your products through the approval process, pass facility inspections, and more. In every issue, you get links to key documents, such as draft and final guidances, warning letters, proposed and final rules, closeout letters, full texts of proposed legislation, GAO reports, and more. Why wait? Click here to subscribe.

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing